ASCO® 2023 Insights: "Dr. Roy Herbst on ADAURA Trial OS Analysis of Adjuvant Osimertinib in Patients With Resected EGFRm Stage IB–IIIA NSCLC"

By ecancer FEATURING Roy Herbst
By ecancer FEATURING Roy Herbst
432 views
June 14, 2023
Comments 0
Login to view comments. Click here to Login